The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessment of quality of life (QOL), cognitive function and depression in a randomized phase II study of abiraterone acetate (ABI) plus prednisone (P) vs enzalutamide (ENZA) for metastatic castrate-resistant prostate cancer (mCRPC).
 
Daniel Khalaf
No Relationships to Disclose
 
Katherine Sunderland
No Relationships to Disclose
 
Bernhard J. Eigl
No Relationships to Disclose
 
Daygen L. Finch
Honoraria - Amgen
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Janssen; Roche
Travel, Accommodations, Expenses - Novartis
 
Conrad D. Oja
No Relationships to Disclose
 
Joanna Vergidis
Honoraria - Astellas Pharma; Bayer; Merck; Novartis; Pfizer; Roche
Consulting or Advisory Role - Astellas Pharma; Bayer
Travel, Accommodations, Expenses - Astellas Pharma
 
Sunil Parimi
No Relationships to Disclose
 
Muhammad Zulfiqar
No Relationships to Disclose
 
Martin Gleave
Employment - OncoGenex
Stock and Other Ownership Interests - OncoGenex
Honoraria - Astellas Pharma; Bayer; Janssen; Oncogenex
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen; Oncogenex
Research Funding - Astellas Pharma; AstraZeneca; Janssen
Patents, Royalties, Other Intellectual Property - OncoGenex - OGX-011, OGX-427
 
Kim N. Chi
Honoraria - Amgen; Astellas Pharma; Janssen; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; ESSA; Janssen; Lilly/ImClone; Sanofi; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Lilly/ImClone (Inst); Novartis (Inst); Oncogenex (Inst); Sanofi (Inst); Teva (Inst); Tokai Pharmaceuticals (Inst)